Journal of Probiotics & Health
Open Access

Research and development new synbiotic product and its clinical effect

3^rd International Conference and Exhibition on Probiotics, Functional & Baby Foods

September 23-25, 2014 Hotel Royal Continental, Naples, Italy

Almagul Kushugulova, S Kozhakhmetov, S Saduakhasova, G Shakhabayeva, Zh Khasenbekova, I Tynybayeva, D Baiskhanova, A Kakimova, T Nurgozhin and Zh Zhumadilov

Scientific Tracks Abstracts: J Prob Health

Abstract :

Introduction: Currently, the functional food is recognized as an alternative to pharmacotherapy. The objective of research is a synbiotic product ?NAR?, which includes probiotics and prebiotics. Probiotics are presented by cultures of Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus acidophilus, Bifidobacteriumlongum, Bifidobacteriumbifidum. The product is also enriched with fish collagen.The goal of this work is to investigate the clinical efficacy of a new synbiotic. Method: Double-blind, randomised, placebo-controlled trial, including 180 adult (age 30-89) with symptomes of metabolic syndrome whowere allocated to placebo or synbiotic group. We enrolled 90 adult in placebo group and 90 in synbiotic group. The two groups were similar for demographic and clinical characteristics. All patients signed a consent letter. The main criteria for inclusion were: Blood pressure: 130/90 mmHg; Raised fastingplasma glucose (FPG): >100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes; Dyslipidemia: triglycerides (TG): =1.695 mmol/L and high-density lipoprotein cholesterol (HDL-C) =0.9 mmol/L (male), =1.0 mmol/L (female); Central obesity:waist:hip ratio >0.90 (male); >0.85 (female), or body mass index >30 kg/m2. All patients underwent clinical and laboratory evaluation, including completeblood tests, glucose test, glycosylated hemoglobin, total cholesterol + triglycerides, cholesterol, LDL, HDL plasma, immunogram, co-program. All patients were interviewed, the questionnaire included 200 questions related to diet, lifestyle andhealth. Synbiotic were used by patients in dose of 200 grams twice a day. The duration of applying the symbiotic were 90 days. Results: In the study group the percentage of colds were significantly lower than in placebo group, the majority of patients reported an improvement in abdominal discomfort, reduction in serum total cholesterol and low-density lipoprotein, weight loss of 8-9 percent in different age groups, stabilized frequency and consistency of stool (judging by the Bristol scale). Conclusion: As a result was exhibited the efficacy of a new synbiotic in adult with metabolic syndrome.